The Female Reproductive toxicity of EDCs project: a human evidence-based screening and dentification approach (FREIA) is EU-funded.
It aims to improve the identification of chemicals that affect women’s health via disruption of the hormone system.
HEAL collaborates on policy and advocacy actions as well as dissemination and communication on health protection. 11 partners contribute from the Netherlands, UK, Denmark, Sweden, Belgium, France, Estonia, and the USA.
The main objective of this project is to provide dedicated, human-relevant, test methods to identify EDCs that cause female reproductive toxicity.
FREIA will generate and integrate scientific data on the effects of EDCs on female reproductive health, specifically on ovarian development and function and the subsequent consequences for female fertility. These data will be used to develop a test strategy with dedicated test methods to assess female reproductive toxicity and provide the basis to develop health preventive options.
Resources from the FREIA project:
- Download the FREIA factsheet ‘Endocrine disrupting chemicals and women’s reproductive health’. Available in English, Dutch, Doric, French and Portuguese (March 2020).
- Download the FREIA infographic ‘Endocrine disrupting chemicals and women’s reproductive health’. Available in English, Catalan, Danish, Mandarin, German, Estonian, Spanish, French, Japanese, Italian, Dutch, Norwegian, Portuguese, Finnish, Swedish and Tagalog (March 2020).
- Sign up to the FREIA newsletter to stay updated about our findings.
- Revisit the FREIA-HEAL webinar series:
- A pragmatic approach to EDC identification – the case study of butylparaben (27 October 2020)
- Introducing the FREIA project: How endocrine disruptors affect women’s reproductive health (in collaboration with the International Federation of Gynecology and Obstetrics – FIGO) (17 February 2020)